Advanced HCP Continuing Education Activity: Innovative Hematology/Oncology Treatment Modalities

Add to Calendar Advanced HCP Continuing Education Activity: Innovative Hematology/Oncology Treatment Modalities 2/20/2020 12:30:00 PM 2/20/2020 4:45:00 PM America/New_York For More Details: https://rutgers.cloud-cme.com/course/courseoverview?EID=3578 Description: This program will include current oncology therapies including biosimiliars, gene therapy, & CAR-T cell therapy, discuss oncology regulatory pathways, & reflect on cultural literacy & roles or wearable technologies impacting patients. Oncology is an ever-growing and changing field of medicine. Merck false MM/DD/YYYY


Date & Location
Thursday, February 20, 2020, 12:30 PM - 4:45 PM, Merck

Overview
This program will include current oncology therapies including biosimiliars, gene therapy, & CAR-T cell therapy, discuss oncology regulatory pathways, & reflect on cultural literacy & roles or wearable technologies impacting patients.  Oncology is an ever-growing and changing field of medicine.

Target Audience
Specialties - General Nursing, General Pharmacy, Internal Medicine, Oncology Pharmacy
Professions - Pharmacist, Physician, Registered Nurse

Objectives

Evaluate the current scope of biosimilars in oncology from pre-approval to post marketing. Discuss the history of gene therapy, its current therapeutic applications, and potential future technologies as it relates to oncology including a discussion of the rationale and incentive to pursue further research in gene therapy. Identify the differences between these two abbreviated approval pathways and their practical applications within the oncology space. Analyze the development, current implementation, and future opportunities in advancements of CAR (chimeric antigen receptor) T-cell therapy. Examine the barriers and disparities of comprehensive oncological treatment among patients from various cultural backgrounds. Assess clinical utility of remote monitoring of cancer patients through wearable technology. 


  1. Understand the definition of biosimilars, review the FDA approval process and analyze their clinical relevance in oncology.
  2. Compare and contrast the similarities and differences of biosimilars to biologics.
  3. Identify the potential risks and benefits of biosimilars.
  4. Define "Gene Therapy" and outline its history and progression throughout the years.
  5. Demonstrate rationale for gene therapy and discuss its role in treatment.
  6. Describe current gene therapies and hypothesize future therapies.
  7. Understand the differences between the 505(b)2 pathway and 505(j) or ANDA pathways.
  8. Examine market opportunities for using the 505(b)2 pathway outside of the innovator and generic spaces.
  9. Discuss pitfalls that may lead to difficulties with using the 505(b)2 pathway.
  10. Use an oncology product as a case example to look at how 505(b) products can be used to gain market share and exclusivity.
  11. Illustrate mechanism of action of CAR-T cell therapy and review its current use in clinical practice.
  12. Explain engineering and individualization of CAR T-cells.
  13. Compare risks versus benefits and identify and discuss future pathways of advancements in CAR T-cell therapy.
  14. Describe the significance of cultural competency and humility in the treatment of cancer patients.
  15. Distinguish the different socioeconomic groups that are affected by the disparity of cultural literacy.
  16. Analyze the different methods for combating educational gaps in cultural literacy.
  17. Evaluate the available evidence for the use of wearable technology and analyze the risks and benefits of utilizing it to monitor cancer patients.
  18. Determine the effects of remote monitoring on patient outcomes and asses their feasibility in oncology practice to improve patient outcomes.

Registration
For Fellows and Merck Colleagues Only:  PharmD's:  When setting up your profiles, make sure to include your NABP# and birth month and birth day if you are seeking CE credits.

Accreditation and Credit Designation

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credits
AMA PRA Category 1 Credits™ (3.00 hours), ACPE Credits (3.00 hours), ANCC Contact Hours (3.00 hours), Non-Physician Attendance (3.00 hours)